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Background: Spine stereotactic body radiation therapy (SBRT) is becoming widely accepted as
ﬁrst-line treatment of oligometastatic spine disease as well as in the postoperative setting. The
reported incidence of myelopathy is very low and guidelines vary widely on the maximum
tolerable dose of the spinal cord and thecal sac.
Methods and materials: Between April 2008 and December 2010, radiation parameters were
exported for 46 patients treated with spine SBRT at the Mayo Clinic. Using an in-house data
mining program, dose-volume histogram constraints were extracted, including dose prescription,
dose fractionation, planning target volume, planning target volume coverage, maximum dose to the
cord, D2cc thecal sac, and D2cc spinal cord. Diagnostic magnetic resonance imaging scans and/or
computed tomography myelograms were fused with the planning set to delineate the cord and
thecal sac for receiver operating characteristic analysis of cord and thecal sac subvolume doses. A
high-resolution planning at-risk volume was created in 1-mm increments for cord (1-7 mm) and the
thecal sac (1-2 mm) to examine dose gradients that might be correlated with toxicity.
Results: No patients experienced myelopathy with a median follow-up of 14 months. The most
common toxicities were pain and nausea. Median values of D2cc maximum dose (maximum dose
received by 2 cc of the organ at risk; biologically equivalent 2-Gy dose maximum [EQD2]) for
cord and thecal sac were 38.5 Gy (range, 7.5-67.9 Gy) and 67.7 Gy (range, 15.5-155.8 Gy),
respectively. Median values for high-dose subvolumes for cord and thecal sac were 2 times higher
than the doses for 5% predicted grade 3 cord toxicity as recommended in the current literature.
Cord D0.1cc[EQD2] 23.8 Gy was correlated with pain ﬂare (n Z 5). Thecal sac D2cc [EQD2]
29.3 Gy was a signiﬁcant indicator of nausea.
Conclusion: Current guidelines may overestimate the risk of myelopathy from spine SBRT. The
current study’s population included both radiation-naïve and retreatment cases, but no myelopathy
was observed despite exceeding recommended spine limits.Conﬂicts of interest: None.
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Spine stereotactic body radiation therapy (SBRT) has
been shown to confer excellent local control and pain
control in both the radiation-naïve and reirradiation
settings.1-4 Spinal cord tolerance in SBRT has been the
subject of debate. The incidence of myelopathy is
exceedingly low. Attempts to delineate the actuarial risk as
well as characterize the cord doses that best correlate with
myelopathy have been difﬁcult. Sahgal et al have published
extensively on this issue, but given the rarity of this
occurrence, to generate an estimate of cord/thecal sac
tolerance in spine SBRT, a pooled multiple institutional
analysis was performed.1,5 Because of differences in target
delineation techniques, limitations in reviewing magnetic
resonance imaging (MRI) data as well as differences in
treatment planning techniques, the authors propose a
maximum point dose (Pmax) to the thecal sac of 12.4 Gy
for single-fraction regimens, 17 Gy in 2 fractions, 20.3 Gy
in 3 fractions, 23 Gy in 4 fractions, and 25.3 Gy in 5
fractions for which the estimated a risk of 5% myelopathy
in the radiation-naïve setting.1 In the reirradiation setting,
estimates are understandably much more conservative and
depend on the prior dose to the cord.5
In contrast, single-institution reports have suggested
myelopathy is rare even with doses to the true cord of 15.7
Gy in the reirradiation setting.4 A recent review of multiple
institutions again conﬁrmed that myelopathy was very rare
even though the maximum dose to the cord varied widely,
to as high as a single point dose of 19 Gy in a single fraction
delivery, even in the reirradiation setting.6 To date, it has
been difﬁcult to precisely predict which patients will have
myelopathy based on maximum dose to the cord.
In the current single-institution study, we examine
dose metrics to both the thecal sac and spinal cord using a
high-risk planning at risk volume (PRV) and correlations
with toxicity in patients treated with spine SBRT.Methods
We have previously published on the Mayo Clinic
experience with spine SBRT in both the reirradiation
and radiation-naïve setting.4 Between April 2008 and
December 2010 (to allow for adequate follow-up of late
toxicity), the radiation plans and dose-volume histogram
(DVH) parameters from 46 of these patients were exported.
These patients were selected because they were the only
patients treated during that period with both adequate
follow-up and available diagnostic MRI for accuratedelineation of the spinal cord and thecal sac. Diagnostic
MRI and/or computed tomography (CT) myelograms, from
each patient, were fused with the CT planning set to contour
the spinal cord and thecal sac. Previous authors have
referenced doses to cord, thecal sac, or a PRV.
High-resolution PRV structures were created using 1-mm
increments for the cord (1-7 mm) and the thecal sac
(1-2 mm). Constructing the PRV set enabled examining
which cord þ PRV margin resulted in distributions similar
to thecal sac. Using an alpha/beta of 2 Gy, the biologically
equivalent 2-Gy dose (EQD2Gy) maximum (Max(2)
[EQD2Gy]) and high-dose subvolumes (Dxcc(2)
[EQD2Gy]) were calculated for xZ 0.1 mL to 1.0 mL in
0.1-mL increments from the DVHs.
Toxicities for pain, nausea, myelitis, fatigue, fracture,
and radiation necrosis were assessed using the Common
Terminology Criteria for Adverse Events, c4.0, criteria.
Although clinical data were available in a prospectively
collected database, all data were veriﬁed by retrospective
chart review. Acute and late toxicity data were documented
at every follow-up in a prospective manner. Additional
information was gleaned from follow up notes and notes
documenting effects during the treatment course.
DVH metrics were calculated for all patients in the
study using an in-house program, DataMiner. De-
pendencies of toxicity scores on DVH metrics were
examined using receiver operator characteristics (ROC)
curve analysis, carried out with R (The R Foundation for
Statistical Computing, www.r-project.org) using an in-
house program, DataMole.7,8 For each DVH metric and
toxicity level, an ROC curve was created and the area
under the curve calculated. A threshold value for each
DVH metric to use in calculating 2  2 contingency ta-
bles for each toxicity level was determined as the value
maximizing the Youden Index on the ROC curve. For
each table, the sensitivity, speciﬁcity, positive predictive
value and negative predictive value were calculated. The
signiﬁcance of the association of groups was calculated
using Fisher exact test (P < .01). Differences in mean
values for groups with and without toxicity were assessed
using t tests for signiﬁcance (P < .05).
Results
Patient demographics
Forty-six patients were available for analysis (Table 1).
Most patients were male (38/46). Only 9/46 patients had
prior external beam radiation therapy to the spine SBRT
site. All patients included in the study had a single course
Table 1 Demographics of spine SBRT patients (N Z 46)
Gender
Male 38
Female 8
Spine level
C spine 8
T spine 27
L spine 11
Prior EBRT to SBRT spine level
Yes 9
No 37
Dose prescriptions
16 Gy/1 fraction 2
18 Gy/1 fraction 8
21 Gy/1 fraction 1
22 Gy/1 fraction 1
24 Gy/1 fraction 4
18 Gy/3 fractions 2
21 Gy/3 fractions 2
24 Gy/3 fractions 17
28 Gy/4 fractions 1
30 Gy/3 fractions 7
35 Gy/5 fractions 1
EBRT, external beam radiation therapy; SBRT, stereotactic body
radiation therapy.
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percent (30/46) patients were treated with a 3-fraction
regimen, whereas most of the remaining patients (16/46)
received a single-fraction regimen. The most common
dose fractionation was 24 Gy/3 fractions.
Acute and late toxicity
With respect to acute toxicity, ﬁve patients developed
pain with spine SBRT (four with grade 1, onewith grade 2).Table 2 Demographics of spine SBRT patients with acute and la
Toxicity CTCAE grade Gender Prior RT
Fatigue 1 Male No
Fatigue 1 Female No
Nausea 1 Male Yes (54 Gy/
Nausea 1 Male No
Nausea 1 Male No
Nausea 2 Male No
Pain 1 Male Yes (20 Gy/
Pain 2 Male No
Pain 1 Male No
Pain 1 Male No
Pain 1 Female No
Myelitis 3 Female No
Paresthesia 3 Male No
Fracture 3 Male No
Fracture 3 Male No
Radionecrosis 3 Male No
CTCAE, Common Terminology Criteria for Adverse Events; SBRT, stereotaFour patients developed nausea (three with grade 1, one
with grade 2). Two patients had documented grade 1
fatigue. One patient experienced acute myelitis and one
developed acute paresthesias.
No patients developed late myelopathy. This was true
even for patients who had more than a 6-month survival
with SBRT (37 of 46 patients lived beyond 6 months
from the end of SBRT). The patient who initially devel-
oped acute myelitis passed away 17.5 months after spine
SBRT with no recurrence in the area treated and no
symptoms of myelopathy. She died of unrelated causes.
Two patients experienced vertebral compression fracture
and one patient developed osteoradionecrosis. Charac-
teristics of the patients with acute and late toxicities are
further characterized in Table 2.Dosimetry and correlation with toxicity
The mean and median values for the Max(2)
[EQD2Gy] to the research cord (0, 1, 2, 3, 4, and 5 mm)
and to the thecal sac (0, 1, and 2 mm) were calculated.
Sample delineation of these structures are shown in
Figures 1 and 2. The median values of the Max(2)
[EDQ2Gy] to the spinal cord and thecal sac were 38.5 Gy
(range, 7.9-67.9 Gy) and 67.7 Gy (range, 15.5-155.8 Gy),
respectively. Distribution of Max(2)[EQD2Gy] values for
the thecal sac corresponded most closely to spinal cord þ
3.5-mm margin (Figure 3). These values were plotted
against the Pmax values published by Sahgal et al1 in
Figure 4. Our median values for high-dose subvolumes
(Dxcc(2)[EQD2Gy] were two times higher than the
doses for 5% predicted distribution of Max(2)[EQD2Gy]
values for the PRV 1 and 2 mm were also evaluated.
These values were also plotted against the suggested
Pmax values1 in Figure 4. Our median values forte toxicity
Spine level SBRT dose/fractionation
T9 24 Gy/3 fractions
T6 30 Gy/3 fractions
30 fractions) L5 24 Gy/3 fractions
T10-11 24 Gy/3 fractions
T10 18 Gy/1 fraction
L2 18 Gy/1 fraction
5 fractions) T5-6 30 Gy/3 fractions
T10-T11 30 Gy/3 fractions
L2 30 Gy/3 fractions
T3 18 Gy/1 fraction
C7 24 Gy/3 fractions
C6 24 Gy/3 fractions
C5 22 Gy/1 fraction
L2 18 Gy/1 fraction
L3 24 Gy/1 fraction
T12 24 Gy/3 fractions
ctic body radiation therapy.
Figure 1 Sample thecal sac 0-, 1-, and 2-mm structures with sample dose-volume histogram.
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and 2 mm were two times higher than the doses for 5%
predicted.
The patients who developed myelitis and paresthesia
each had a Max(2)[EQD2Gy] to the cord of 54.7 Gy and
24.8 Gy, respectively. The Max(2)[EQD2Gy] levels to
the thecal sac were 72 Gy and 92.7 Gy. Neither patient
had prior radiation therapy to the sites treated. Both
patients had complete resolution of symptoms within 1
month of treatment.
Spine SBRT was very well-tolerated and acute effects
were uncommon, as described previously. The most
common acute events were acute back pain (5/46 patients)
and nausea (4/46 patients). ROC analysis demonstrated
freedom from pain 1 was signiﬁcant for cord Dxcc
[EQ2Gy]  volume () dependent thresholds. Cord D2cc
[EQ2Gy]  15.2 Gy was most signiﬁcant (Fisher exact
test <0.0004) with highest ROC area under the curveFigure 2 Sample cord 0-, 1-, 2-, 3-, 4-, 5-, 6-, and 7-m(0.85). Thecal sac D0.1cc[EQD2Gy] 29.3 Gy was a
signiﬁcant indicator for nausea 1.
Local control and overall survival
Median follow-up was 14 months and median survival
from the end of SBRT spine treatment was also 14
months (range, 1-64 months). At the time of analysis, 34
of 46 patients had died of causes unrelated to spine
SBRT. Only one patient of 46 in the current series had
documented local progression.
Discussion
The current study raises questions about the sensitivity
and tolerance of the spinal cord to high doses of radiation.
Despite our patients receiving 2 times the limit that maym structures with sample dose-volume histogram.
Figure 3 Determining thecal sac dose correlation with spinal
cord expansion margin. EQ2Gy, equivalent dose in 2 Gy/frac-
tion; Max(2), maximum dose in 2 Gy equivalent fractions to the
spinal cord or thecal sac.
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observe any patients with this complication after spine
SBRT. The majority of our patients lived well beyond 6
months with adequate follow-up to assess for these
complications.
The seminal study in delineating the risk of myelop-
athy from spine SBRT was derived from Sahgal et al’s
retrospective review.1 In that series, spine metastases
SBRT databases from MD Anderson Cancer Center,Figure 4 Myelopathy risk per Sahgal et al and Mayo Clinic
minimum EQD2 to thecal sac. 2GyEQ, dose in equivalent 2-Gy
fractions; EQ2Gy, biologically equivalent dose in 2-Gy fractions.University of Toronto, and University of California at San
Francisco were used to identify a cohort of 66 controls
and nine patients who developed myelopathy. In that
study, median survival was 15 months, which is compa-
rable to our current patient population. Normalized bio-
logical equivalent dose or 2 Gy biologically equivalent
doses (nBED) was calculated and a logistic regression
model was generated to predict 1% and 5% radiation
myelopathy. This study suggested that the maximum dose
to the thecal sac (nBED Gy2/2) for a single-fraction spine
SBRT treatment was 12.4 Gy and 20.3 Gy for a 3-fraction
regimen. However, this study is limited by the heteroge-
neous population across three different institutions and
that 7/9 radiation myelopathy patients had dose parame-
ters to the thecal sac that were well below the dose con-
straints proposed by the authors. The authors also report
that the thecal sac actually corresponds to a cord PRV of
the cord þ 1.5-mm margin, which is more rigorous than
our correlation of dose that may reﬂect contouring dif-
ferences in the thecal sac between our institutions.
In the current study, our maximum thecal sac doses
were twice those reported by Sahgal et al. The median
values for high dose subvolumes (Dxcc(2)[EQD2Gy]
assuming a 2-mm PRV to more closely align with the
suggested guidelines were two times higher than the doses
for 5% predicted. We have previously reported on 85
spine lesions treated with SBRT in 66 patients with a
median follow-up of 8.2 months, none of whom devel-
oped myelopathy. The 46 patients included in this study
were from the same cohort who had spinal cord and thecal
sac contours available for analysis and with further
follow-up and median survival of 14 months, there were
still no patients who have developed myelopathy. The risk
of myelopathy is truly unknown. One recent review
examined 1400 patients, mostly reported in retrospective
reviews, and proposed that the risk of myelopathy is less
than 1%.9 Chang et al demonstrated no myelopathy with a
21.3-month median follow-up among 63 patients treated
with spine SBRT on a phase 1/2 trial.10 The University of
Pittsburgh has extensive experience, with 1075 patients
treated with spine SBRT between 1996 and 2005.11 In
that series, they identiﬁed only 6 patients who developed
late radiation myelopathy.11 The low incidence of
myelopathy may be correlated with poor survival in spinal
metastases.
In the past 10 years, chemotherapy has markedly
improved systemic control and radiation oncologists are
entering an era of aggressive oligometastatic treatment.
Median survival after spine SBRT varies but has been
reported to be as high as 30 months.12 However, survival
in spinal metastases depends on a variety of factors,
including performance status, neurological compromise
before treatment, control of the primary and systemic
disease, histology, age, and comorbidities. A recent study
generated a recursive partitioning study for predicting
survival after SBRT.13 Their model of 174 patients
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unfavorable histologies (renal cell, melanoma, sarcoma)
as well as gender, age, Karnofsky performance scale,
primary control, extraosseous metastases, time from pri-
mary diagnosis, dose of SBRT, extent of spine disease,
and prior spine surgery. The limitation of this study was
its short median follow-up of 8.9 months. Class 1 patients
were deﬁned as time to diagnosis of spinal metastasis
from primary disease >30 months, Karnofsky perfor-
mance scale >70 and had a median survival of 21.1
months. Class 3 patients were diagnosed <30 months
from initial primary diagnosis and age >70 with a median
survival of 2.4 months. Class 2 had a median survival of
8.7 months. The difference in median survival between
radiation-resistant and radiosensitive disease was 11 and
14 months, respectively.13 In the current study, 75% of
the patients had already died at the time of analysis after
spine SBRT despite excellent local control.
Given the low incidence of myelopathy and variable
survival of patients after spine SBRT, it is very difﬁcult to
deﬁnitively correlate dosimetric data with adverse out-
comes and to accurately predict which patients may
develop myelopathy. Our study is limited by small
numbers as well as its retrospective nature. However, it
does conﬁrm that adherence to current guidelines confers
a low risk of myelopathy and that in patients whose
survival may be limited but who may beneﬁt from spine
SBRT, such as in the reirradiation setting, the risk of
myelopathy may be low even if cord limits are above
current recommendations. Prospective trials such as Ra-
diation Therapy Oncology Group 0631 will help provide
insight into ongoing debates about the safety and tolera-
bility of spine SBRT and possible clinical predictors of
rare events such as late radiation myelopathy.References
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